speeding ticket, page-17

Following the manufacture of sufficient supplies of the drug compound by ANP?s technology partner, Isis
Pharmaceuticals Inc., ANP has now commenced formulation of this raw material into injectible product
to be used in the clinical trial. This drug product formulation work should be completed in April 2011.




The first stage of the trial to
demonstrate the safety and tolerability of ATL1103 in healthy volunteers is expected to be completed by
the end of 2011.

so this year for results human trial for ALT 1103

and befor that maybe ann for partner of ALT 1101